ArticleInternational ophthalmology2026
Evaluation of hyperreflective spots as a novel biomarker in patients with glaucoma.
Article in International ophthalmology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate hyperreflective spots (HRS) detected by optical coherence tomography (OCT) in healthy and glaucomatous eyes and their correlation with retinal ganglion cell (RGC) loss.
methodsA total of 65 patients with primary open-angle glaucoma (POAG) and 65 healthy controls were enrolled, and data were collected from one eye of each participant. In glaucoma patients, the eye with better visual acuity was selected; if equal, the eye with the higher OCT image quality was included. In the control group, the eye with the higher OCT image quality was selected for analysis. OCT scans of the fovea's thinnest section were analyzed, and an area 3000 µm wide at the center was selected. HRS were defined as small spots (≤ 30 µm) with moderate reflectivity and no shadowing. HRS counts were compared between groups, and correlations with OCT parameters associated with RGC loss were assessed.
resultsThe mean age was similar between groups (glaucoma: 62.48 ± 19.77 years; control: 59.75 ± 6.65 years; P = 0.085). Inter-rater agreement for HRS counts was excellent (ICC = 0.927, 95% CI: 0.89-0.94). Glaucoma patients had significantly higher HRS counts than controls (29.65 ± 7.68 vs. 11.86 ± 5.05, P < 0.001). HRS counts positively correlated with vertical and horizontal cupping diameters (r = 0.45, P < 0.001) and negatively correlated with neuroretinal rim area (r = - 0.46, P < 0.001), total RNFL thickness (r = - 0.39, P < 0.001), and mean GCC thickness (r = - 0.43, P < 0.001). Correlation coefficients were similar after adjusting for age, intraocular pressure (IOP), and signal strength index (SSI).
conclusionsHRS strongly correlate with RGC and RNFL loss in glaucoma and may serve as as a valuable biomarker in the follow-up of glaucoma.
Indexed as
Identifiers
41733702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.